The firms teamed up to build the plant – a mini version of Boehringer’s German bio facility – three years ago, with plans for a mutually beneficial partnership afterwards.
Speaking to in-PharmaTechnologist and Outsourcing-Pharma at this year’s Interphex in New York, Kemwell’s director of corporate development Christian Ahlmark said the firm would support clinical and small scale commercial production through the plant, whilst Boehringer would take large-scale clients.
The plant – which will produce monoclonal and peptides for small scale projects, amongst other things – will be completed in Q3 this year.
Ahlmark also spoke to us about Kemwell’s recently opened cGMP (current good manufacturing practice) oral liquid dose plant in India.
“That is serving a global market, where previously our Indian operations were solely for India, and it’s capable of 300m bottles of oral liquid product per year,” he said.